April 28th 2024
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Neoadjuvant Cabozantinib/Nivolumab Feasible For Borderline Resectable Patients with HCC
February 19th 2021Preliminary data showing the neoadjuvant use of cabozantinib and nivolumab to be feasible for borderline resectable patients with hepatocellular carcinoma that can lead to potentially curative resection.
Read More
Second-Line Pembrolizumab Shows Continued OS and PFS Improvement in Advanced HCC
January 18th 2021In patients with previously treated advanced hepatocellular carcinoma (HCC), single-agent pembrolizumab (Keytruda) maintained numerical improvement in survival (OS), updated findings randomized phase 3 KEYNOTE-240 trial show.
Read More
Survival Benefit Maintained With Atezolizumab Plus Bevacizumab in Advanced HCC
January 17th 2021Results from the phase 3 IMbrave150 clinical trial showed that the combination of atezolizumab and bevacizumab continued to demonstrate improvement in survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.
Read More
Comparable Survival Observed With Regorafenib in HCC in Real-World Versus Clinical Settings
January 5th 2021In an interview with Targeted Oncology, Richard S. Finn, MD, discussed the real-world data from the REFINE study, which is exploring the outcomes of patients with unresectable hepatocellular carcinoma who received treatment with regorafenib.
Read More